256 reports of this reaction
5.9% of all ARSENIC TRIOXIDE reports
#1 most reported adverse reaction
ELECTROCARDIOGRAM QT PROLONGED is the #1 most commonly reported adverse reaction for ARSENIC TRIOXIDE, manufactured by Cephalon, LLC. There are 256 FDA adverse event reports linking ARSENIC TRIOXIDE to ELECTROCARDIOGRAM QT PROLONGED. This represents approximately 5.9% of all 4,344 adverse event reports for this drug.
Patients taking ARSENIC TRIOXIDE who experience electrocardiogram qt prolonged should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ELECTROCARDIOGRAM QT PROLONGED is moderately reported among ARSENIC TRIOXIDE users, representing a notable but not dominant share of adverse events.
In addition to electrocardiogram qt prolonged, the following adverse reactions have been reported for ARSENIC TRIOXIDE:
The following drugs have also been linked to electrocardiogram qt prolonged in FDA adverse event reports:
ELECTROCARDIOGRAM QT PROLONGED has been reported as an adverse event in 256 FDA reports for ARSENIC TRIOXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ELECTROCARDIOGRAM QT PROLONGED accounts for approximately 5.9% of all adverse event reports for ARSENIC TRIOXIDE, making it one of the most commonly reported side effect.
If you experience electrocardiogram qt prolonged while taking ARSENIC TRIOXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.